Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-26T21:45:17.019Z Has data issue: false hasContentIssue false
  • English
  • Français

Usefulness of ischemia-modified albumin for assessment of the effects of small ventricular septal defects on the pulmonary vascular bed

Part of: Echocardiography Ventricular Septal Defect (VSD)

Published online by Cambridge University Press:  22 March 2021

Pinar Dervisoglu Open the ORCID record for Pinar Dervisoglu [Opens in a new window]  and
Taliha Oner Open the ORCID record for Taliha Oner [Opens in a new window]
Pinar Dervisoglu*
Affiliation:
Sakarya University, Faculty of Medicine, Department of Pediatric Cardiology, Sakarya, Turkey
Taliha Oner
Affiliation:
University of Health Sciences, Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Pediatric Cardiology, Istanbul, Turkey
*
Author for correspondence: Dr P. Dervisoglu, MD, Sakarya University, Medical Faculty Department of Pediatric Cardiology, Adnan Menderes Street, Sakarya 54100, Turkey. Tel: +090 505 9231960; Fax: +90 264 2745086. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Pulmonary vascular damage may be associated with oxidative stress in congenital heart diseases. We investigated whether small ventricular septal defects have an effect on the pulmonary bed.

Methods:

This prospective cohort study included 100 patients with small ventricular septal defects and 75 healthy controls. Ischemia-modified albumin, high-sensitivity C-reactive protein, and various cardiovascular parameters were assessed in both groups.

Results:

The mean ischemia-modified albumin level was significantly higher in patients with small ventricular septal defects (0.62 ± 0.17 absorbance units) than in the control group (0.51 ± 0.09 absorbance units; p < 0.001). The mean high-sensitivity C-reactive protein level was significantly higher in the ventricular septal defects group (3.72 ± 1.57) than in the control group (2.45 ± 0.89; p < 0.001). The ischemia-modified albumin levels in patients with left ventricular internal diameter end diastole and end sistole and main pulmonary artery z-scores ≥ 2 were significantly higher than patients whose z-scores were <2. The ischemia-modified albumin and high-sensitivity C-reactive protein levels were positively correlated in the small ventricular septal defects group (rho = 0.742, p < 0.001). Receiver operating characteristic analyses showed that at the optimal cut-off value of ischemia-modified albumin for the prediction of pulmonary involvement was 0.55 absorbance units with a sensitivity of 60%, specificity of 62% (area under the curve = 0.690, p < 0.001).

Conclusions:

We demonstrated the presence of oxidative stress and higher ischemia-modified albumin levels in small ventricular septal defects, suggesting that ischemia-modified albumin might be a useful biomarker for evaluating the effects of small ventricular septal defects on the pulmonary bed.

Keywords

Childhoodischemia-modified albuminpulmonary vasculary bedventricular septal defect
Type
Original Article
Information
Cardiology in the Young , Volume 31 , Issue 7 , July 2021 , pp. 1207 - 1212
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Tretter, JT, Benson, L, Crucean, A, Spicer, DE, Anderson, RH. Ventricular septal defect. In: Anderson, RH, Krishna, K, Mussato, KA, et al. (eds). Anderson’s Pediatric Cardiology, 4th edn. Elsevier, Philadelphia, 2020: 555–584.Google Scholar
Yan, L, Chen, X, Talati, M, et al. Bone marrow-derived cells contribute to the pathogenesis of pulmonary arterial hypertension. Am J Respir Crit Care Med 2016; 193: 898–909.CrossRefGoogle Scholar
Hiress, ML, Tu, L, Ricard, N, et al. Proinflammatory signature of the dysfunctional endothelium in pulmonary hypertension. Role of the macrophage migration inhibitory factor/CD74 complex. Am J Respir Crit Care Med 2015; 192: 983–997.CrossRefGoogle ScholarPubMed
Fichtlscherer, S, Rosenberger, G, Walter, DH, Breuer, S, Dimmeler, S, Zeiher, AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000–1006.CrossRefGoogle ScholarPubMed
Ridker, PM, Hennekens, CH, Buring, JE, Rifai, N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843.CrossRefGoogle Scholar
Lamblin, N, Mouquet, F, Hennache, B, et al. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J 2005; 26: 2245–2250.CrossRefGoogle ScholarPubMed
Roy, D, Quiles, J, Gaze, DC, Collinson, P, Kaski, JC, Baxter, GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006; 92: 113–114.CrossRefGoogle ScholarPubMed
Turedi, S, Gunduz, A, Mentese, A, et al. Investigation of the possibility of using ischemia-modified albumin as a novel and early prognostic marker in cardiac arrest patients after cardiopulmonary resuscitation. Resuscitation 2009; 80: 994–999.CrossRefGoogle ScholarPubMed
Hacker, M, Hoyer, HX, la Fouge‘re, C, et al. Effects of peripheral vascular intervention on ischemia-modified albumin. Coronary Artery Dis 2007; 18: 375–379.CrossRefGoogle ScholarPubMed
Abbas, AE, Fortuin, FD, Schiller, NB. Echocardiographic determination of mean pulmonary artery pressure. Am J Cardiol 2003; 92: 1373–1376.CrossRefGoogle ScholarPubMed
Li, J, Cao, Y, Ma, XJ, et al. Roles of miR-1–1 and miR-181c in ventricular septal defects. Int J Cardiol 2013; 168: 1441–1446.CrossRefGoogle ScholarPubMed
Zhao, Y, Samal, E, Srivastava, D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005; 14: 214–220.CrossRefGoogle Scholar
Catalucci, D, Latronico, MV, Condorelli, G. MicroRNAs control gene expression: importance for cardiac development and pathophysiology. Ann N Y Acad Sci 2008; 1123: 20–29.CrossRefGoogle ScholarPubMed
Lequier, LL, Nikaidoh, H, Leonard, S, et al. Preoperative and postoperative endotoxemia in children with congenital heart disease. Chest 2000; 117: 1706–1712.CrossRefGoogle ScholarPubMed
Sharma, R, Bolger, AP, Li, W, et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol 2003; 92: 188–193.CrossRefGoogle ScholarPubMed
Opotowsky, AR, Baraona, F, Owumi, J, et al. Galectin-3 is elevated and associated with adverse outcomes in patients with single-ventricle Fontan circulation. J Am Heart Assoc 2016; 5: e002706.CrossRefGoogle ScholarPubMed
Pignatelli, P, Menichelli, D, Pastori, D, Violi, F. Oxidative stress and cardiovascular disease: new insights. Kardiol Pol 2018; 76: 713–722.CrossRefGoogle ScholarPubMed
Maagaard, M, Heiberg, J, Eckerström, F, Rex, BAC, Ringgaard, S, Hjortdal, VE. Biventricular morphology in adults born with a ventricular septal defect. Cardiol Young 2018; 28: 1379–1385.CrossRefGoogle ScholarPubMed
Moller, T, Brun, H, Fredriksen, PM, et al. Right ventricular systolic pressure response during exercise in adolescents born with atrial or ventricular septal defect. Am J Cardiol 2010; 105: 1610–1616.CrossRefGoogle ScholarPubMed
Maagaard, M, Heiberg, J, Hjortdal, VE. Small, unrepaired ventricular septal defects reveal poor exercise capacity compared with healthy peers: a prospective, cohort study. Int J Cardiol 2017; 227: 631–634.CrossRefGoogle ScholarPubMed
Rogowski, O, Shnizer, S, Wolff, R, Lewis, BS, Amir, O. Increased serum levels of oxidative stress are associated with hospital readmissions due to acute heart failure. Cardiology 2011; 118: 33–37.CrossRefGoogle ScholarPubMed
Jena, I, Nayak, SR, Behera, S, et al. Evaluation of ischemia-modified albumin, oxidative stress, and antioxidant status in acute ischemic stroke patients. J Nat Sci Biol Med 2017; 8: 110–113.CrossRefGoogle ScholarPubMed
Roy, D, Quiles, J, Sharma, R, et al. Ischemia modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem 2004; 50: 1656–1660.CrossRefGoogle ScholarPubMed
Roy, D, Quiles, J, Gaze, DC, Collinson, P, Kaski, JC, Baxter, GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006; 92: 113–114.CrossRefGoogle ScholarPubMed
Morrow, DA, de Lemos, JA, Sabatine, MS, Antman, EM. The search for a biomarker of cardiac ischemia. Clin Chem 2003; 49: 537–539.CrossRefGoogle ScholarPubMed
Sinha, MK, Gaze, DC, Tippins, JR, Collinson, PO, Kaski, JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003; 107: 2403–2405.CrossRefGoogle ScholarPubMed